Completed
Study of Talabostat and Cisplatin in Advanced Melanoma
What is being tested
Data Collection
Who is being recruted
Melanoma+9
+ Neoplasms
+ Neoplasms by Histologic Type
Over 18 Years
+14 Eligibility Criteria
How is the trial designed
Treatment Study
Phase 2
Interventional
Summary
Principal SponsorPoint Therapeutics
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner
The purpose of this study is to assess the antitumor activity and safety of the combination of talabostat and cisplatin in patients with metastatic melanoma.
Official TitleStudy of Talabostat and Cisplatin in Advanced Melanoma
Principal SponsorPoint Therapeutics
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Treatment Study
These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Conditions
Criteria
Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
MelanomaNeoplasmsNeoplasms by Histologic TypeNeoplasms by SiteNeoplasms, Germ Cell and EmbryonalNeoplasms, Nerve TissueSkin DiseasesSkin NeoplasmsSkin and Connective Tissue DiseasesNeuroectodermal TumorsNevi and MelanomasNeuroendocrine Tumors
Criteria
5 inclusion criteria required to participate
Histologically or cytologically confirmed melanoma that is metastatic (unresectable Stage IV per AJCC 2002)
Patients with measurable disease defined as at least one measurable index lesion with clearly defined margins
ECOG Performance Status of 0, 1, or 2
Expected survival ≥12 weeks
Show More Criteria
9 exclusion criteria prevent from participating
More than 1 prior chemotherapy or biotherapy regimen for metastatic melanoma
Radiation therapy to >50% of the bone marrow. Patients must not have had prior radiotherapy to index lesions unless they have clearly progressive disease in this site or there is measurable disease outside the area of prior radiation.
Clinically significant laboratory abnormalities
Symptomatic CNS metastases
Show More Criteria
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 13 locations
Suspended
University of Arkansas Medical Sciences
Little Rock, United StatesOpen University of Arkansas Medical Sciences in Google MapsSuspended
Cancer Institute Medical Group, Inc.
Santa Monica, United StatesSuspended
University of Colorado Health Sciences Center
Aurora, United StatesSuspended
Cancer Center of Florida
Ocoee, United StatesCompleted13 Study Centers